Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic A

• Status: Completed
• Trial end date: 2018-10-10

Summary

Cytomegalovirus (CMV) infection is the most frequent opportunistic viral infection after transplantation. It is associated with an increased incidence of acute rejection and lower graft and patient survivals. The goal of this study is to demonstrate that an immunosuppressive regimen associating everolimus and reduced dose of cyclosporine A can prevent acute rejection episodes as efficiently as standard regimen but also efficiently reduce the incidence of CMV infection at 6 months post-transplantation.

• Phase: Phase 4

Details

• Lead Sponsor: University Hospital, Bordeaux
• Collaborator: Novartis
• Treatments: Cyclosporine; Cyclosporins; Everolimus; Immunosuppressive Agents; Methylprednisolone; Mycophenolate mofetil; Mycophenolic Acid; Sirolimus